Microvascular Dysfunction in Hypertensive Disorders of Pregnancy: Implications for Evaluation, Treatment, and Further Research

Kathryn J. Lindley,Victor G. Davila-Roman

DOI: https://doi.org/10.1161/circimaging.124.016816

2024-05-23

Circulation Cardiovascular Imaging

Abstract:Circulation: Cardiovascular Imaging, Volume 17, Issue 5, Page e016816, May 1, 2024.

radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems

What problem does this paper attempt to address?

Emerging Pharmacologic Interventions for Pre-Eclampsia Treatment

Xiao Zhang,Yue Chen,Dong-li Sun,Xiaojun Zhu,Xia Ying,Yao,Weidong Fei,Cai-hong Zheng

DOI: https://doi.org/10.1080/14728222.2022.2134779

IF: 6.797

2022-01-01

Expert Opinion on Therapeutic Targets

Abstract:ABSTRACT Introduction Pre-eclampsia is a serious pregnancy complication and a major global concern for the mortality of both mother and fetus. Existing symptomatic treatments do not delay disease progression; thus, timely delivery of the baby is the most effective measure. However, the risk of various maternal and fetal injuries remains. Areas covered In this review, we summarize potential strategies for pharmacologic interventions in pre-eclamptic therapy. Specifically, we discuss the pathophysiological process of various effective candidate therapeutics that act on potential pathways and molecular targets to inhibit key stages of the disease. We refer to this pathogenesis-focused drug discovery model as a pathogenesis–target–drug (P–T–D) strategy. Finally, we discuss the introduction of nanotechnologies to improve the safety and efficacy of therapeutics via their specific placental targeting ability and placental retention effects. Expert opinion Despite the active development of novel pharmacological treatments based on our current knowledge of pre-eclamptic pathogenesis, investigations are still in the early phase. Thus, further exploration of the pathological mechanisms, integrated with the P–T–D strategy and novel nanosystems, could encourage more effective and safer strategies. Such advances could lead to a shift from expectant management to mechanistic-based therapy for pre-eclampsia.
Progress in Soluble Vascular Endothelial Growth Factor Receptor-1 and Preeclampsia

WU Ying,CHEN Dan-qing,WANG Bo

2012-01-01

Abstract:Pre-eclampsia is a complication of pregnancy characterized by hypertension and proteinuria that results in maternal and neonatal mortality and morbidity.Although the etiology remains unclear,it seems to be initiated by placental factors that enter the maternal circulation and may cause endothelial dysfunction.Recently,anti-angiogenic factors such as endoglin,the soluble form of vascular endothelial growth factor receptor(sFlt-1) as well as the placental growth factor have been found to be associated with the onset of pre-eclampsia.This review will summarize our current understanding of molecular structure of sFlt-1,signal pathways,with an emphasis on its role in the pathogenesis of preeclampsia and regulative factors.
Maternal Microvascular Dysfunction During and After Preeclamptic Pregnancy

Kelsey S Schwartz,Anna E Stanhewicz

DOI: https://doi.org/10.1002/cphy.c240003

IF: 5.8

2024-10-10

Comprehensive Physiology

Abstract:Preeclampsia, a pregnancy disorder characterized by de novo hypertension and maternal multisystem organ dysfunction, is the leading cause of maternal mortality worldwide and is associated with a fourfold greater risk of cardiovascular disease throughout the lifespan. Current understanding of the etiology of preeclampsia remains unclear, due in part to the varying phenotypical presentations of the disease, which has hindered the development of effective and mechanism-specific treatment or...

physiology
Hypertensive disorders of pregnancy & vascular dysfunction

Anna Palatnik,Jacquelyn Kulinski

DOI: https://doi.org/10.3389/fcvm.2024.1411424

IF: 3.6

2024-05-31

Frontiers in Cardiovascular Medicine

Abstract:Hypertensive disorders of pregnancy (HDP) are a leading cause of maternal and fetal morbidity and mortality. One of the more severe HDP diagnoses is preeclampsia, which is recognized as a sex-specific cardiovascular risk enhancer with long-term implications for women's health, increasing lifetime risk of ischemic heart disease, stroke, and heart failure. Though the mechanisms accounting for the increased risk of cardiovascular disease following HDP are not yet well understood, vascular dysfunction has been implicated. In this perspective piece, we summarize the existing evidence for vascular dysfunction in HDP with a focus on non-invasive assessments, highlight advances in the field, and suggest future directions for improving risk stratification of women with HDP.

cardiac & cardiovascular systems
A Systematic Review of Vascular Structure and Function in Pre-eclampsia: Non-invasive Assessment and Mechanistic Links

Shady Kirollos,Michael Skilton,Sanjay Patel,Clare Arnott

DOI: https://doi.org/10.3389/fcvm.2019.00166

2019-11-15

Abstract:Hypertensive disorders of pregnancy, such as pre-eclampsia, are known to be independently associated with the development of premature cardiovascular disease (CVD) in women. In pre-eclampsia, the placenta secretes excess anti-angiogenic factors into the maternal circulation, leading to widespread endothelial damage, and inflammation. This endothelial damage is evidenced to persist beyond the acute illness. However, whether it is permanent and responsible for the elevated rates of premature CVD seen in this at-risk group remains unclear. A systematic review of the available literature with respect to vascular structure and function prior to, during and after a pregnancy complicated by pre-eclampsia was performed. Studies non-invasively assessing vascular structure using carotid intima-media thickness (CIMT), retinal microvasculature caliber, CT coronary angiogram, or coronary calcium scores were included. Vascular function was assessed using brachial flow-mediated dilation (FMD), pulse wave analysis (PWA), and peripheral arterial tonometry (PAT). In total 59 articles were included (13 CIMT, 5 CTCA/Ca score, five retinal microvasculature, 27 FMD, 7 PAT, and 14 PWV/PWA), consisting of prospective and retrospective cohort, and case-control studies. Change in vascular structure was evidenced with significant increases in CIMT by 73-180 μm greater than that of non-affected women. This is tempered by other studies reporting resolution of structural changes postpartum, highlighting the need for further research. Accelerated coronary calcification and plaque deposition was identified, with greater rates of increased calcium scores and subclinical coronary artery disease shown by CTCA in women with a history of pre-eclampsia at 30 years postpartum. Impaired endothelial function was consistently reported prior to, during and immediately after pregnancy as evidenced by differences in FMD of 1.7-12.2% less than non-affected women, an increase in PWV by 13.2-26%, and reduced retinal microvascular caliber and arterial elasticity indices. The evidence was less conclusive for the persistence of long-term endothelial dysfunction. Understanding the underlying mechanistic links between pre-eclampsia and CVD is a key step to identifying targeted therapies aimed at "repairing the endothelium" and attenuating risk. This review has highlighted the need for a greater understanding of vascular structure and function following pre-eclampsia through high quality studies with large sample sizes, particularly in the longer postpartum period when clinical CVD disease starts to manifest.
Hypertensive states of pregnancy

E Rubio Gonzalez,A M Huerta Arroyo,F Garcia Benasach,T Gijon Conde

DOI: https://doi.org/10.1016/j.hipert.2023.11.006

Abstract:Hypertensive disorders in pregnancy (HDP) remain a leading cause of pregnancy-related maternal and foetal morbidity and mortality worldwide, including chronic hypertension, gestational hypertension, and pre-eclampsia. Affected women and newborns also have an increased risk of cardiovascular disease later in life, independent of traditional cardiovascular disease risks. Despite these risks, recommendations for optimal diagnosis and treatment have changed little in recent decades, probably due to fear of the foetal repercussions of decreased blood pressure and possible drug toxicity. In this document we review the diagnostic criteria and classification of (HDP), as well as important aspects regarding pathophysiology and early detection that allows early identification of women at risk, with the aim of preventing both immediate and long-term consequences. Prophylactic treatment with aspirin is also reviewed early and a therapeutic approach is carried out that involves close maternal and foetal monitoring, and if necessary, the use of safe drugs in each situation. This review aims to provide an updated vision for the prevention, diagnosis, and treatment of HDP that is useful in our usual clinical practice.
Retinal oximetry and microvascular assessment after hypertensive pregnancy complications

Sissel Hoel,Kjartan Moe,Meryam Sugulle,Goran Petrovski,Nina Charlotte B. B. Veiby,Anne Cathrine Staff

DOI: https://doi.org/10.1111/aos.16651

2024-02-13

Acta Ophthalmologica

Abstract:Purpose Women with hypertensive disorders of pregnancy (HDP) are at increased risk of developing premature cardiovascular disease (CVD). The mechanisms behind this are not fully understood, but microvascular alterations have been documented in retinal arterioles and venules. The aim of this study was to use non‐invasive retinal imaging to investigate the structural and functional properties of arterioles, venules and capillaries in this patient group. Methods We examined 27 women with previous HDP and 23 controls at 3 years postpartum. The retinal microvasculature was assessed by vessel calibre measurements, retinal oximetry and optical coherence tomography angiography. Differences were analysed using non‐parametric tests and multiple regression analyses, adjusted for age and body mass index. Results Median arteriolar oxygen saturation (SaO2; 94.2% vs. 93.0%), venular oxygen saturation (SvO2; 60.1% vs. 62.4%) and arteriovenous saturation difference (AV‐difference; 32.8% vs. 32.3%) were similar across groups. Capillary vessel density (VD; 46.2% vs. 46.3%), skeletonised VD (VSD; 21.3 vs. 21.1 mm/mm2) and vessel diameter index (21.65 vs. 21.86) were also comparable. In the HDP group, mean arterial pressure (MAP) was positively correlated with AV‐difference (R2 = 0.209) and negatively correlated with arteriolar diameter (CRAE; r2 = 0.382). Conclusions Structural microvascular alterations appear not to be key biomarkers for CVD risk after HDP as early as 3 years postpartum in otherwise healthy women. Further studies are needed to evaluate whether such changes occur later in life. MAP was associated with AV‐difference only in the HDP group, suggesting specific mechanisms affecting functional microvascular properties in these women.

ophthalmology
Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview

Renata Cífková

DOI: https://doi.org/10.1007/s40292-023-00582-5

Abstract:Hypertensive disorders in pregnancy are associated with increased risk of maternal, fetal, and neonatal morbidity and mortality. It is important to distinguish between pre-existing (chronic) hypertension and gestational hypertension, developing after 20 weeks of gestation and usually resolving within 6 weeks postpartum. There is a consensus that systolic blood pressure ≥ 170 or diastolic blood pressure ≥ 110 mmHg is an emergency and hospitalization is indicated. The selection of the antihypertensive drug and its route of administration depend on the expected time of delivery. The current European guidelines recommend initiating drug treatment in pregnant women with persistent elevation of blood pressure ≥ 150/95 mmHg and at values > 140/90 mmHg in women with gestational hypertension (with or without proteinuria), with pre-existing hypertension with the superimposition of gestational hypertension, and with hypertension with subclinical organ damage or symptoms at any time during pregnancy. Methyldopa, labetalol, and calcium antagonists (the most data are available for nifedipine) are the drugs of choice. The results of the CHIPS and CHAP studies are likely to reduce the threshold for initiating treatment. Women with a history of hypertensive disorders in pregnancy, particularly those with pre-eclampsia, are at high risk of developing cardiovascular disease later in life. Obstetric history should become a part of the cardiovascular risk assessment in women.
Pathophysiology of Preeclampsia-Induced Vascular Dysfunction and Implications for Subclinical Myocardial Damage and Heart Failure

Leslee J Shaw,Krishna Patel,Anuradha Lala-Trindade,Helen Feltovich,Luciana Vieira,Amy Kontorovich,Cande Ananth,Viviany R Taqueti,Lindsey Mitrani,Toni Stern,Chelsea DeBolt,Nathan Kase,R Theodore Smith,Jagat Narula,Roxana Mehran,Angela Bianco,Deepak L Bhatt,Joanne L Stone

DOI: https://doi.org/10.1016/j.jacadv.2024.100980

2024-05-14

Abstract:Tragically, preeclampsia is a leading cause of pregnancy-related complications and is linked to a heightened risk for morbid and fatal cardiovascular disease (CVD) outcomes. Although the mechanism connecting preeclampsia to CVD risk has yet to be fully elucidated, evidence suggests distinct pathways of early and late preeclampsia with shared CV risk factors but with profound differences in perinatal and postpartum risk to the mother and infant. In early preeclampsia, <34 weeks of gestation, systemic vascular dysfunction contributes to near-term subclinical myocardial damage. Hypertrophy and diastolic abnormalities persist postpartum and contribute to early onset heart failure (HF). This HF risk remains elevated decades later and contributes to premature death. Black women are at the highest risk of preeclampsia and HF. These findings support closer monitoring of women postpartum, especially for those with early and severe preeclampsia to control chronic hypertension and reduce the potentially preventable sequelae of heightened CVD and HF risk.
Hemodynamic pathways of gestational hypertension and preeclampsia

Wilfried Gyselaers

DOI: https://doi.org/10.1016/j.ajog.2021.11.022

IF: 9.8

2022-02-01

American Journal of Obstetrics and Gynecology

Abstract:Gestational hypertension and preeclampsia are the 2 main types of hypertensive disorders in pregnancy. Noninvasive maternal cardiovascular function assessment, which helps obtain information from all the components of circulation, has shown that venous hemodynamic dysfunction is a feature of preeclampsia but not of gestational hypertension. Venous congestion is a known cause of organ dysfunction, but its potential role in the pathophysiology of preeclampsia is currently poorly investigated. Body water volume expansion occurs in both gestational hypertension and preeclampsia, and this is associated with the common feature of new-onset hypertension after 20 weeks of gestation. Blood pressure, by definition, is the product of intravascular volume load and vascular resistance (Ohm's law). Fundamentally, hypertension may present as a spectrum of cardiovascular states varying between 2 extremes: one with a predominance of raised cardiac output and the other with a predominance of increased total peripheral resistance. In clinical practice, however, this bipolar nature of hypertension is rarely considered, despite the important implications for screening, prevention, management, and monitoring of disease. This review summarizes the evidence of type-specific hemodynamic profiles in the latent and clinical stages of hypertensive disorders in pregnancy. Gestational volume expansion superimposed on an early gestational closed circulatory circuit in a pressure- or volume-overloaded condition predisposes a patient to the gradual deterioration of overall circulatory function, finally presenting as gestational hypertension or preeclampsia-the latter when venous dysfunction is involved. The eventual phenotype of hypertensive disorder is already predictable from early gestation onward, on the condition of including information from all the major components of circulation into the maternal cardiovascular assessment: the heart, central and peripheral arteries, conductive and capacitance veins, and body water content. The relevance of this approach, outlined in this review, openly invites for more in-depth research into the fundamental hemodynamics of gestational hypertensive disorders, not only from the perspective of the physiologist or the scientist, but also in assistance of clinicians toward understanding and managing effectively these severe complications of pregnancy.
Hypertensive Disorders of Pregnancy and Future Cardiovascular Health

Karen Melchiorre,Basky Thilaganathan,Veronica Giorgione,Anna Ridder,Alessia Memmo,Asma Khalil

DOI: https://doi.org/10.3389/fcvm.2020.00059

IF: 3.6

2020-04-15

Frontiers in Cardiovascular Medicine

Abstract:Hypertensive disorders of pregnancy (HDP) occur in almost 10% of gestations. These women are known to have higher cardiovascular morbidity and mortality later in life in comparison with parous controls who had normotensive pregnancies. Several studies have demonstrated that women with preeclampsia present in a state of segmental impaired myocardial function, biventricular chamber dysfunction, adverse biventricular remodeling, and hypertrophy, a compromised hemodynamic state and indirect echocardiographic signs of localized myocardial ischemia and fibrosis. These cardiac functional and geometric changes are known to have strong predictive value for cardiovascular disease in non-pregnant subjects. A "dose effect" response seems to regulate this relationship with severe HDP, early-onset HDP, coexistence of fetal growth disorders, and recurrence of HDP resulting in poorer cardiovascular measures. The mechanism underlying the relationship between HDP in younger women and cardiovascular disease later in life is unclear but could be explained by sharing of pre-pregnancy cardiovascular risk factors or due to a direct impact of HDP on the maternal cardiovascular system conferring a state of increased susceptibility to future metabolic or hemodynamic insults. If so, the prevention of HDP itself would become all the more urgent. Shortly after delivery, women who experienced HDP express an increased risk of classic cardiovascular risk factors such as essential hypertension, renal disease, abnormal lipid profile, and diabetes with higher frequency than controls. Within one or two decades after delivery, this group of women are more likely to experience premature cardiovascular events, such as symptomatic heart failure, myocardial ischemia, and cerebral vascular disease. Although there is general agreement that women who suffered from HDP should undertake early screening for cardiovascular risk factors in order to allow for appropriate prevention, the exact timing and modality of screening has not been standardized yet. Our findings suggest that prevention should start as early as possible after delivery by making the women aware of their increased cardiovascular risk and encouraging weight control, stop smoking, healthy diet, and daily exercise which are well-established and cost-effective prevention strategies.

cardiac & cardiovascular systems
A Comprehensive Review of Hypertension in Pregnancy

Reem Mustafa,Sana Ahmed,Anu Gupta,Rocco C. Venuto

DOI: https://doi.org/10.1155/2012/105918

2012-01-01

Journal of Pregnancy

Abstract:Hypertension is the most common medical disorder encountered during pregnancy. Hypertensive disorders are one of the major causes of pregnancy-related maternal deaths in the United States. We will present a comprehensive update of the literature pertinent to hypertension in pregnancy. The paper begins by defining and classifying hypertensive disorders in pregnancy. The normal vascular and renal physiological changes which occur during pregnancy are detailed. We will summarize the intriguing aspects of pathophysiology of preeclampsia, emphasizing on recent advances in this field. The existing diagnostic tools and the tests which have been proposed for screening preeclampsia are comprehensively described. We also highlight the short- and long-term implications of preeclampsia. Finally, we review the current management guidelines, goals of treatment and describe the potential risks and benefits associated with various antihypertensive drug classes. Preeclampsia still remains an enigma, and the present management focuses on monitoring and treatment of its manifestations. We are hopeful that this in depth critique will stimulate the blossoming research in the field and assist practitioners to identify women at risk and more effectively treat affected individuals.

English Else
Hypertension Management in Pregnancy

Kimberly Ryan,Lidija McGrath,Kathleen Brookfield

DOI: https://doi.org/10.1146/annurev-med-050423-085626

2024-11-27

Annual Review of Medicine

Abstract:Chronic hypertension and preeclampsia spectrum disorders in pregnancy are important contributors to long-term maternal morbidity and mortality. Due to physiologic changes during pregnancy and the postpartum period, blood pressure expectations differ between primary care providers and obstetricians. The goal of this article is to describe the pathophysiology and definitions of hypertension in the obstetric context and review current evidence for management during pregnancy and the postpartum period. Longitudinal follow-up with a primary care provider after delivery is crucial for long-term cardiovascular risk reduction in hypertensive patients.

medicine, research & experimental
Hypertensive Disorders of Pregnancy and the Cardiovascular System: Causes, Consequences, Therapy, and Prevention

Kristin Darwin,Ahmet A. Baschat,Arthur J. Vaught

DOI: https://doi.org/10.1055/a-2051-2127

2023-04-11

American Journal of Perinatology

Abstract:Hypertensive disorders of pregnancy continue to be significant contributors to adverse perinatal outcome and maternal mortality, as well as inducing life-long cardiovascular health impacts that are proportional to the severity and frequency of pregnancy complications. The placenta is the interface between the mother and fetus and its failure to undergo vascular maturation in tandem with maternal cardiovascular adaptation by the end of the first trimester predisposes to hypertensive disorders and fetal growth restriction. While primary failure of trophoblastic invasion with incomplete maternal spiral artery remodeling has been considered central to the pathogenesis of preeclampsia, cardiovascular risk factors associated with abnormal first trimester maternal blood pressure and cardiovascular adaptation produce identical placental pathology leading to hypertensive pregnancy disorders. Outside pregnancy blood pressure treatment thresholds are identified with the goal to prevent immediate risks from severe hypertension >160/100 mm Hg and long-term health impacts that arise from elevated blood pressures as low as 120/80 mm Hg. Until recently, the trend for less aggressive blood pressure management during pregnancy was driven by fear of inducing placental malperfusion without a clear clinical benefit. However, placental perfusion is not dependent on maternal perfusion pressure during the first trimester and risk-appropriate blood pressure normalization may provide the opportunity to protect from the placental maldevelopment that predisposes to hypertensive disorders of pregnancy. Recent randomized trials set the stage for more aggressive risk-appropriate blood pressure management that may offer a greater potential for prevention for hypertensive disorders of pregnancy. Key Points Optimal management of maternal blood pressure to prevent preeclampsia and its risks is undefined. Early gestational rheological damage to the intervillous space predisposes to preeclampsia and FGR. First trimester blood pressure management may need to aim for normotension to prevent preeclampsia. Received: 20 May 2022 Accepted: 06 March 2023 Accepted Manuscript online: 09 March 2023 Article published online: 10 April 2023 © 2023. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

pediatrics,obstetrics & gynecology
New views on endothelial dysfunction in gestational hypertension and potential therapy targets

Xueqin Feng,Yanping Liu,Yingying Zhang,Yumeng Zhang,Huan Li,Qiutong Zheng,Na Li,Jiaqi Tang,Zhice Xu

DOI: https://doi.org/10.1016/j.drudis.2021.03.001

IF: 8.369

2021-06-01

Drug Discovery Today

Abstract:The placenta has vital roles in metabolite exchange, fetal growth, and pre-eclampsia (PE). In this review, we discuss the pathogenesis of hypertension in pregnancy (PE), focusing on four major theories to explain PE, discussing endothelial roles in those theories. We focus in particular on the roles of nitric oxide (NO) and prostacyclin (PCI2) in placental endothelium, and propose new hypotheses for the influence and mechanisms of endothelial NO and PCI2 signaling pathways in PE.

pharmacology & pharmacy
Long-Term Cardiovascular Disease Risk in Women After Hypertensive Disorders of Pregnancy: Recent Advances in Hypertension

Kavia Khosla,Sarah Heimberger,Avery Tung,Sajid Shahul,Anne Cathrine Staff,Sarosh Rana,Kristin M. Nieman

DOI: https://doi.org/10.1161/hypertensionaha.121.16506

IF: 9.8968

2021-10-01

Hypertension

Abstract:Patients with a history of hypertensive disorders of pregnancy (HDP) suffer higher rates of long-term cardiovascular events including heart failure, coronary artery disease, and stroke. Cardiovascular changes during pregnancy can act as a natural stress test, subsequently unmasking latent cardiovascular disease in the form of HDP. Because HDP now affect 10% of pregnancies in the United States, the American Heart Association has called for physicians who provide peripartum care to promote early identification and cardiovascular risk reduction. In this review, we discuss the epidemiology, pathophysiology, and outcomes of HDP-associated cardiovascular disease. In addition, we propose a multi-pronged approach to support cardiovascular risk reduction for women with a history of HDP. Additional research is warranted to define appropriate blood pressure targets in the postpartum period, optimize the use of pregnancy history in risk stratification tools, and clarify the effectiveness of preventive interventions. The highest rates of HDP are in populations with poor access to resources and quality health care, making it a major risk for inequity of care. Interventions to decrease long-term cardiovascular disease risk in women following HDP must also target disparity reduction.

peripheral vascular disease
Impaired microvascular insulin-dependent dilation in women with a history of gestational diabetes.

Kelsey S. Schwartz,Paola V. Hernandez,Grace S. Maurer,Elizabeth M. Wetzel,Mingyao Sun,Diana I. Jalal,Anna E. Stanhewicz

DOI: https://doi.org/10.1152/ajpheart.00223.2024

2024-07-27

Abstract:American Journal of Physiology-Heart and Circulatory Physiology, Ahead of Print.
Microvascular Dysfunction as a Systemic Disease: A Review of the Evidence

Daniel S Feuer,Eileen M Handberg,Borna Mehrad,Janet Wei,C Noel Bairey Merz,Carl J Pepine,Ellen C Keeley

DOI: https://doi.org/10.1016/j.amjmed.2022.04.006

Abstract:Microvascular dysfunction describes a varied set of conditions that includes vessel destruction, abnormal vasoreactivity, in situ thrombosis, and fibrosis, which ultimately results in tissue damage and progressive organ failure. Microvascular dysfunction has a wide array of clinical presentations, ranging from ischemic heart disease to renal failure, stroke, blindness, pulmonary arterial hypertension, and dementia. An intriguing unifying hypothesis suggests that microvascular dysfunction of specific organs is an expression of a systemic illness that worsens with age and is accelerated by vascular risk factors. Studying relationships across a spectrum of microvascular diseases affecting the brain, retina, kidney, lung, and heart may uncover shared pathologic mechanisms that could inform novel treatment strategies. We review the evidence that supports the notion that microvascular dysfunction represents a global pathologic process. Our focus is on studies reporting concomitant microvascular dysfunction of the heart with that of the brain, kidney, retina, and lung.
EP17.11: Microvascular function assessed by laser speckle contrast imaging in pregnancies complicated by pre‐eclampsia and fetal growth restriction

V. Seravalli,M. Huri,I. Abati,A. Vallario,C. Bartolini,G. Impastato,M. Santalucia,M. Di Tommaso

DOI: https://doi.org/10.1002/uog.28668

2024-09-11

Ultrasound in Obstetrics and Gynecology

Abstract:Ultrasound in Obstetrics &Gynecology, Volume 64, Issue S1, Page 264-265, September 2024.

radiology, nuclear medicine & medical imaging,obstetrics & gynecology,acoustics
Cardiovascular Complications in Pregnancy

Avisha Shah,Jay Patel,Ameesh Isath,Hafeez Ul Hassan Virk,Hani Jneid,Carolyn M. Zelop,Shilpi Mehta-Lee,Katherine E. Economy,Martha Gulati,Chayakrit Krittanawong

DOI: https://doi.org/10.1007/s11936-023-01000-8

2023-08-26

Current Treatment Options in Cardiovascular Medicine

Abstract:We review the epidemiology, risk factors, presentation, pathophysiology, diagnosis, peripartum management, and postpartum follow-up of chronic hypertension, hyperlipidemia, acute myocardial infarction, stroke, heart failure, pulmonary embolism, and atrial fibrillation.

Microvascular Dysfunction in Hypertensive Disorders of Pregnancy: Implications for Evaluation, Treatment, and Further Research

Emerging Pharmacologic Interventions for Pre-Eclampsia Treatment

Progress in Soluble Vascular Endothelial Growth Factor Receptor-1 and Preeclampsia

Maternal Microvascular Dysfunction During and After Preeclamptic Pregnancy

Hypertensive disorders of pregnancy & vascular dysfunction

A Systematic Review of Vascular Structure and Function in Pre-eclampsia: Non-invasive Assessment and Mechanistic Links

Hypertensive states of pregnancy

Retinal oximetry and microvascular assessment after hypertensive pregnancy complications

Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview

Pathophysiology of Preeclampsia-Induced Vascular Dysfunction and Implications for Subclinical Myocardial Damage and Heart Failure

Hemodynamic pathways of gestational hypertension and preeclampsia

Hypertensive Disorders of Pregnancy and Future Cardiovascular Health

A Comprehensive Review of Hypertension in Pregnancy

Hypertension Management in Pregnancy

Hypertensive Disorders of Pregnancy and the Cardiovascular System: Causes, Consequences, Therapy, and Prevention

New views on endothelial dysfunction in gestational hypertension and potential therapy targets

Long-Term Cardiovascular Disease Risk in Women After Hypertensive Disorders of Pregnancy: Recent Advances in Hypertension

Impaired microvascular insulin-dependent dilation in women with a history of gestational diabetes.

Microvascular Dysfunction as a Systemic Disease: A Review of the Evidence

EP17.11: Microvascular function assessed by laser speckle contrast imaging in pregnancies complicated by pre‐eclampsia and fetal growth restriction

Cardiovascular Complications in Pregnancy